Cover image of the article: Randomized Controlled Trial on Comparison of the Course of Hyperthyroid Patients with and Without Antithyroid Drugs During the Immediate Post Radioactive Iodine Treatment Period

Image Credit:Int J Endocrinol Metab

Randomized Controlled Trial on Comparison of the Course of Hyperthyroid Patients with and Without Antithyroid Drugs During the Immediate Post Radioactive Iodine Treatment Period

Authors

MFR Gafate1, L Mercado-Asis2,*
1Section of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Sto Tomas Hospital, Philippnes
2Section of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Sto Tomas Hospital, m_gafate@yahoo.com, Philippnes
*Corresponding Author: Section of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Sto Tomas Hospital, m_gafate@yahoo.com, Philippnes. Email: m_gafate@yahoo.com

International Journal of Endocrinology and Metabolism:Vol. 6, issue 1; 1-5
Published online:Jan 31, 2008
Article type:Research Article
Received:Jun 17, 2007
Accepted:Dec 26, 2007
How to Cite:Gafate M, Mercado-Asis L. Randomized Controlled Trial on Comparison of the Course of Hyperthyroid Patients with and Without Antithyroid Drugs During the Immediate Post Radioactive Iodine Treatment Period. Int J Endocrinol Metab. 2008;6(1):. doi:

Abstract

This study was done to compare the clinical course of hyperthyroid patients with and without anti-thyroid drugs immediately post radioactive iodine treatment. Materials and Methods: Patients with mild to moderate hyperthyroidism, aged 18 to 60 years, were divided into 2 groups, those who received RAI plus anti-thyroid (ATD) (propylthiouracil 100 mg q8H) (group A) and those who received RAI only (group B). Fixed doses of 8 mCi 131I were given and symptoms were scored daily for 3 weeks, using 3-severe, 2-moderate, 1-mild scores. Descriptive analysis using mean and standard deviation was used to determine the demographic profiles and Mann Whitney t-test for independent samples was utilized to com-pare the symptoms between the two groups. All statistical tests were pegged at .05 alpha level and p-values less than .05 were considered sig-nificant. Results: There were 3 males and 5 females in group A (n=8, mean age: 38±12.82 yrs) and 2 males and 6 females in group B, (n=8, mean age: 41.37±15.14 yrs). TSH was suppressed in both groups and the mean FT4 for group A was 13.87±16.51 pmol/L, and for group B was 28.51±15.86 pmol/L. There was no significant dif-ference in age, FT4 and TSH. Mean scores were as follows: (Group A vs. Group B), week one: 1.36 vs. 1.55 (p=0.01); week two: 1.08 vs. 0.94 (p= 0.110), and week three: 0.71 vs. 0.92 (p= 0.006). A highly significant decrease in symptoms was noted in week three. Conclusion: Analysis of our data showed that patients given ATD immediately post RAI ex-perienced lesser symptoms of thyrotoxicosis dur-ing the first and third week after RAI treatment, favoring treatment with ATD.

Highlights

Full Text

Full text is available in PDF

Copyright

© 2008, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Oct
2005
Comparison of Outcome in Radioiodine Induced Euthyroid and Hypothyroid Patients

Comparison of Outcome in Radioiodine Induced Euthyroid and Hypothyroid Patients

F Shekholeslami,
L Ataie,
M Hedayati,
Y Mehrabi,
F Azizi

Shekholeslami F, Ataie L, Hedayati M, Mehrabi Y, Azizi F. Comparison of Outcome in Radioiodine Induced Euthyroid and Hypothyroid Patients. Int J Endocrinol Metab. 2005;3(4):. doi:

31
Mar
2005
The prevalence of Graves’ disease and related factors recurrence following discontinuation of antithyroid agents

The prevalence of Graves’ disease and related factors recurrence following discontinuation of antithyroid agents

S Kalantary

Kalantary S. The prevalence of Graves’ disease and related factors recurrence following discontinuation of antithyroid agents. J Inflamm Dis. 2024;8(4):e155096. doi:

30
Jun
2011
Evaluation of glucose tolerance in methimazole and Radioiodine treated Graves’ patients

Evaluation of glucose tolerance in methimazole and Radioiodine treated Graves’ patients

javad kiani,
Vahid Yusefi,
Maryam Tohidi,
Yadollah Mehrabi,
Fereidoun Azizi

kiani J, Yusefi V, Tohidi M, Mehrabi Y, Azizi F. Evaluation of glucose tolerance in methimazole and Radioiodine treated Graves’ patients. Int J Endocrinol Metab. 2010;8(3):e94642. doi:

2
Jan
2024
Sustained Euthyroidism during Thionamide Antithyroid Drug Treatment: Comparison of Short- and Long-term Methimazole Therapy

Sustained Euthyroidism during Thionamide Antithyroid Drug Treatment: Comparison of Short- and Long-term Methimazole Therapy

Navid Saadat,
Safdar Masoumi,
Mohammad Karim Shahrzad,
Fereidoun Azizi

Saadat N, Masoumi S, Shahrzad MK, Azizi F. Sustained Euthyroidism during Thionamide Antithyroid Drug Treatment: Comparison of Short- and Long-term Methimazole Therapy. Int J Endocrinol Metab. 2024;22(1):e140956. doi: https://doi.org/10.5812/ijem-140956

31
Jul
2008
Before Moving Towards Recombinant Thyrotropin, Can We Benefit From Anti-Thyroid Drugs? A Case Study

Before Moving Towards Recombinant Thyrotropin, Can We Benefit From Anti-Thyroid Drugs? A Case Study

A Soltani,
N Rahimian,
Z Rahbar,
H Moosapour

Soltani A, Rahimian N, Rahbar Z, Moosapour H. Before Moving Towards Recombinant Thyrotropin, Can We Benefit From Anti-Thyroid Drugs? A Case Study. Int J Endocrinol Metab. 2008;6(3):. doi:

More by these authors

MFR GafatePubMedScholar
L Mercado-AsisPubMedScholar
Share
Cited by
Metrics